CN116407667A - Liquid embolic agent and preparation method and application thereof - Google Patents

Abstract

The invention relates to a liquid embolic agent, a preparation method and application thereof. The liquid embolic agent comprises the following components in percentage by mass: a polymer, a developer, and a solvent; the developer is at least one of hollow microspheres made of metal, hollow microspheres made of alloy and hollow microspheres made of metal compound. The liquid embolic agent developer adopts the hollow microspheres with the specific materials, can obtain the average density which is greatly lower than that of the materials, and further can obtain higher storage stability after even dispersion. The hollow microspheres with better suspension stability are beneficial to pushing the liquid embolic agent, so that the liquid embolic agent can be dispersed forwards more sequentially; the developer with the same mass has larger volume, and the larger volume can reduce the risk of being taken away along with the diffusion of the solvent in the blood vessel with smaller volume, thereby effectively reducing the sedimentation and reflux risks of the developer and the loss of the developer and obtaining better developing effect.

Description

Liquid embolic agent and its preparation method and application

technical field

The invention relates to the technical field of medical devices, in particular to a liquid embolic agent and its preparation method and application.

Background technique

Embolization can also be called embolization therapy (embolotherapy), which is to controlly inject embolic agents into the supply vessels of diseased organs through arterial or intravenous catheters, so as to make them occluded and interrupt the blood supply, so as to control bleeding, treat tumors and Vascular disease and the purpose of eliminating the function of diseased organs. At present, interventional embolization technology is widely used in the clinical treatment of vascular abnormalities such as cerebral arteriovenous malformation (AVM) and cerebral arteriovenous fistula (DVF). The interventional embolic agent is a reagent that has the function of embolizing tumor blood vessels, which can form an embolism in the lumen of tumor blood vessels, and then block the lumen of the blood vessels, and finally achieve the purpose of ischemia and necrosis of the tumor.

At present, there are many types of interventional embolic agents, classified according to their status, including solid embolic agents and liquid embolic agents. Although the embolization process of solid embolic agents is relatively simple, it requires a large-diameter microcatheter, which cannot enter the lesion site close to the AVM for more precise embolization, and the problem of vascular recanalization is prone to occur after particle embolization. Therefore, solid embolic materials are mostly used for preoperative embolization, which is difficult to meet the needs of curative embolization.

Compared with solid embolic agents, liquid embolic agents have stronger fluidity. They can be directly injected into tumor tissue and evenly filled with diseased blood vessels through thinner microcatheters. They are completely suitable for patients with different sizes and shapes. Tumor, so that no gap is left between the tumor tissue and the embolization material, so as to block the blood vessel, reduce the possibility of blood vessel recanalization, and achieve precise and permanent embolization.

Currently, there are two types of liquid embolic agents that are widely used clinically, including adhesive liquid embolic agents and non-adhesive liquid embolic agents. Onyx liquid embolic agent is a suspension formed by mixing ethylene vinyl alcohol copolymer, dimethyl sulfoxide (DMSO) and micron tantalum powder in a certain proportion. It is a new type of intravascular non-adhesive liquid Embolic agents are also one of the most commonly used non-adhesive liquid embolic agents. The working principle of Onyx liquid embolic agent is that ethylene vinyl alcohol copolymer is insoluble in water but soluble in dimethyl sulfoxide, and nanoscale tantalum powder is used as a developer. When the liquid embolic agent is mixed with an aqueous solution (such as blood) When in contact, dimethyl sulfoxide quickly diffuses into the aqueous solution, and the ethylene vinyl alcohol copolymer precipitates into a solid, which acts as an embolism. purpose of blood flow. The developer micron-sized tantalum powder can be developed under X-rays, and then obtained by the developed image, so as to facilitate the treatment and diagnosis of diseases.

However, in long-term practical applications, it has been found that tantalum is a VB group element with an atomic number of 73. It has good radiopaque properties, a density of 16.65g/cm ³ , and is insoluble in water and most solvents. Settling, so micron-sized tantalum powder is used as the developer of the liquid embolic agent, and the micron-sized tantalum powder needs to be vigorously stirred or shaken for a long time to promote its uniform dispersion in the polymer dimethyl sulfoxide solution to form tantalum powder Suspension; and it needs to be used within a short time after uniform dispersion to avoid developing performance of the developer. At the same time, in the process of pushing the liquid embolic agent, there will inevitably be the problem of developer sedimentation, which will lead to the loss of part of the developer and part of the ethylene vinyl alcohol copolymer, so that the concentration of the developer that finally acts on the diseased site will decrease. Lead to poor developing effect.

Contents of the invention

Based on this, it is necessary to provide a liquid embolic agent with better storage stability and developing effect, its preparation method and application.

The present invention is achieved through the following technical solutions.

One aspect of the present invention provides a liquid embolic agent, comprising: a polymer, a developer, and a solvent in terms of mass fraction;

Wherein, the developer is at least one of hollow microspheres made of metal, hollow microspheres made of alloy and hollow microspheres made of metal compound.

In some of these embodiments, the hollow microsphere is a surface porous structure;

And/or, the particle size of the hollow microspheres is 0.1 μm to 200 μm;

And/or, the wall thickness of the hollow microspheres is 20nm-20μm;

And/or, the volume of the hollow part of the hollow microspheres accounts for 30%-80%.

In some of these embodiments, the metal is one of gold, silver, platinum, iridium, chromium, tantalum, bismuth, cobalt, tungsten, and barium;

The alloy is at least two of gold, silver, platinum, iridium, chromium, tantalum, bismuth, cobalt, tungsten and barium;

The metal compound is a metal salt, metal oxide, metal carbide and metal nitrogen insoluble in the solvent formed by at least one of gold, silver, platinum, iridium, chromium, tantalum, bismuth, cobalt, tungsten and barium at least one of the compounds.

In some of the embodiments, by mass fraction, the polymer is 2%-20%, the developer is 10%-40%, and the solvent is 40%-88%.

In some of the embodiments, the weight average molecular weight of the polymer is 10,000-400,000.

In some of these embodiments, the polymer is at least one of a hydrophobic polymer and an amphiphilic polymer;

And/or, the solvent is at least one of biocompatible organic solvent, water and buffer.

In some of these embodiments, the polymer is any one of polyolefin, polyolefin alcohol, polymethacrylate, polyurethane, polyester, polyether, polysiloxane and polyamide, or at least one of them two copolymers;

And/or, the solvent is at least one of dimethyl sulfoxide, N-methylpyrrolidone, ethanol, isopropanol, water and buffer.

Another aspect of the present invention provides a method for preparing a liquid embolic agent, comprising the steps of:

Mix the components in the liquid embolic agent described in any one of the above evenly.

In some of these embodiments, the preparation method also includes the preparation step of the developer:

Using polymer microspheres as a template, forming a metal layer, alloy layer or metal compound layer on the surface of the polymer microspheres, removing the core polymer microsphere template to obtain hollow microspheres made of metal, alloy or metal compound .

Another aspect of the present invention provides the application of the liquid embolic agent described in any one of the above in the preparation of medical interventional devices or interventional therapy drugs.

Another aspect of the present invention provides a medical interventional device, which is characterized in that it comprises a device body and the liquid embolic agent described in any one of the above-mentioned devices disposed in the device body.

The above-mentioned liquid embolic agent, the developer uses the hollow microspheres of the above-mentioned specific types of materials as the developer. structure, which can obtain an average density much lower than that of its material, and its average bulk density is also greatly reduced, and its suspension stability in liquid embolic agents is higher, which in turn can obtain higher storage stability after uniform dispersion. The hollow microspheres with better suspension stability have a plasticizing effect in the polymer solution formed by the polymer and the solvent, which is beneficial to the push of the liquid embolic agent, so that the liquid embolic agent can be diffused forward in a more orderly manner; at the same time, The developer of the same quality has a larger volume, and the larger volume can also reduce the risk of being taken away with the diffusion of solvent in the smaller blood vessel, thereby effectively reducing the sedimentation of the developer and avoiding the clogging of the developer sedimentation The forward diffusion path of the subsequent liquid embolic agent also effectively reduces the risk of reflux, thereby reducing the loss of developer, and can use less developer and developer metal to provide a better developing effect.

Description of drawings

Fig. 1 is the structural representation of the hollow microsphere that one embodiment of the present invention adopts;

Fig. 2 is a half-sectional view of the hollow microsphere shown in Fig. 1;

Fig. 3 is a schematic diagram of mutual dispersion of the components of the liquid embolism prepared in one embodiment of the present invention;

Explanation of reference signs:

11. Hollow structure; 12. Hole.

Detailed ways

In order to facilitate the understanding of the present invention, the following will describe the present invention more fully and give preferred embodiments of the present invention. However, the present invention can be embodied in many different forms and is not limited to the embodiments described herein. It should be understood that the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the technical field of the invention. The terms used herein in the description of the present invention are for the purpose of describing specific embodiments only, and are not intended to limit the present invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

In addition, the terms "first" and "second" are used for descriptive purposes only, and cannot be interpreted as indicating or implying relative importance or implicitly specifying the quantity of indicated technical features. Thus, the features defined as "first" and "second" may explicitly or implicitly include at least one of these features. In the description of the present invention, "plurality" means at least two, such as two, three, etc., unless otherwise specifically defined.

One embodiment of the present invention provides a liquid embolic agent, which comprises, by mass fraction: 2% to 20% of a polymer, 10% to 40% of a developer, and 40% to 88% of a solvent;

Wherein, the developer is at least one of hollow microspheres made of metal, hollow microspheres made of alloy and hollow microspheres made of metal compound.

A developer refers to an agent that is visible under X-rays. It can be understood that the metal, alloy or metal compound in the above-mentioned developer contains a developable metal, and a developable metal refers to a metal visible under X-rays.

Alloys in the present invention include metal alloys formed from two different metals.

The metal compound in the present invention refers to a compound formed of a metal and a non-metal element.

It can be understood that the imaging agent of the above-mentioned liquid embolic agent may contain one or more hollow microspheres. When containing multiple hollow microspheres, each hollow microsphere can be made of different metal materials, different alloy materials or different metal compound materials, or contain at least two of metal materials, alloy materials and metal compound materials material.

The above-mentioned liquid embolic agent, the developer uses the hollow microspheres of the above-mentioned specific types of materials as the developer. structure, which can obtain an average density much lower than that of its material, and its average bulk density is also greatly reduced, and its suspension stability in liquid embolic agents is higher, which in turn can obtain higher storage stability after uniform dispersion. The hollow microspheres with better suspension stability have a plasticizing effect in the polymer solution formed by the polymer and the solvent, which is beneficial to the push of the liquid embolic agent, so that the liquid embolic agent can be diffused forward in a more orderly manner; at the same time, The developer of the same quality has a larger volume, and the larger volume can also reduce the risk of being taken away with the diffusion of solvent in the smaller blood vessel, thereby effectively reducing the sedimentation of the developer and avoiding the clogging of the developer sedimentation The forward diffusion path of the subsequent liquid embolic agent also effectively reduces the risk of reflux, thereby reducing the loss of developer, and can use less developer and developer metal to provide a better developing effect.

In some of these embodiments, the aforementioned metals are gold (Au), silver (Ag), platinum (Pt), iridium (Ir), chromium (Cr), tantalum (Ta), bismuth (Bi), cobalt (Co), One of tungsten (W) and barium (Ba). These metals have good visibility under X-rays.

Further, the above-mentioned alloy is gold (Au), silver (Ag), platinum (Pt), iridium (Ir), chromium (Cr), tantalum (Ta), bismuth (Bi), cobalt (Co), tungsten (W) And at least two of barium (Ba), that is, alloy metal material.

Further, the above metal compounds are gold (Au), silver (Ag), platinum (Pt), iridium (Ir), chromium (Cr), tantalum (Ta), bismuth (Bi), cobalt (Co), tungsten (W ) and barium (Ba) formed at least one of at least one of metal salts, metal oxides, metal carbides and metal nitrides insoluble in the above solvents. For example, the material of the metal compound is silver halide, bismuth oxide, tantalum carbide, barium sulfate, tungsten oxide, tantalum nitride, tantalum oxide and the like.

Further, the above-mentioned metal salts, metal oxides, metal carbides and metal nitrides are water-insoluble and non-organic solvent-soluble compounds.

In some of these embodiments, the hollow microspheres are superficially porous. This can further reduce the average density of the hollow microspheres.

Figure 1 and Figure 2 show the schematic structure of the developer. It can be seen from FIG. 1 that the surface of the developer has a porous structure with holes 12 . It can be seen from the sectional view of FIG. 2 that the inside of the developer is a hollow structure 11 . In the specific example shown in FIG. 1 and FIG. 2 , the developer is a hollow microsphere with a hollow portion 11 , and the surface of the hollow microsphere (ie, the surface wall of the hollow microsphere) also has holes 12 . The components of the liquid embolic agent formed by using the developer with this structure are in a state of mutual dispersion in the mixed state before curing, as shown in FIG. 3 .

It can be understood that, in other embodiments, the developer can be a hollow microsphere with a hollow portion 11 , and the surface of the hollow microsphere does not have a hole 12 .

In some of these embodiments, the particle size of the hollow microspheres is 0.1 μm to 200 μm, such as 0.1 μm, 0.3 μm, 0.5 μm, 0.7 μm, 0.9 μm, 1 μm, 2 μm, 10 μm, 20 μm, 50 μm, 100 μm, 120 μm, 150 μm , 200 μm. On the basis of ensuring that the average density is lower than the polymer solution formed by the polymer and the solvent to ensure the suspension stability of the hollow microspheres in the polymer solution, or appropriately increase the particle size of the hollow microspheres to further reduce the Reflux risk. Further, the particle size of the hollow microspheres is 0.5 μm-100 μm.

It can be understood that the hollow microspheres can be monodisperse particles with a uniform particle size, or polydisperse particles with various particle sizes.

In some of these embodiments, the wall thickness of the hollow microspheres is 20nm-20μm, such as 20nm, 30nm, 40nm, 60nm, 60nm, 70nm, 80nm, 90nm, 100nm, 200nm, 400nm, 1μm, 2μm, 5μm, 10μm, 20μm . Since the hollow microspheres contain the above-mentioned developable metals, and these metals themselves have a high density, the wall thickness of the hollow microspheres does not need to be too thick, and the thin wall thickness of the hollow microspheres can meet the requirements of the developing effect. In this way, hollow microspheres with thinner walls can obtain smaller average density and larger volume.

Preferably, the average density of the hollow microspheres can be determined by controlling the wall thickness of the hollow microspheres and the particle size of the hollow microspheres. The average density can make the microspheres easy to disperse in the solution and difficult to settle. Further, by controlling the wall thickness of the hollow microspheres and the particle size of the hollow microspheres, the volume ratio of the hollow part of the hollow microspheres can be controlled to be 30%-80%, more preferably 40%-60%. Controlling the hollow part of the hollow microspheres within this range can make the average density of the hollow microspheres neither too large nor too small, and can maintain good suspension stability in the liquid embolic agent, which is beneficial to the embolism of the embolic agent. Good forward diffusion is beneficial to reduce reflux.

In some of the embodiments, the preparation method of the above-mentioned hollow microspheres may be a polymer template method. Specifically, the polymer template method refers to the preparation of polymer microspheres with a certain particle size by means of emulsion polymerization or self-assembly, and then depositing a metal layer, an alloy layer, or a metal layer on the surface of the polymer microspheres. The surface grows grafted to form a metal compound layer. The metal, alloy or metal compound layer can be stably present and separated, and the polymer microsphere template in the core is removed by elution with a specific solvent, or removed by calcination at a specific temperature or other means Core polymer microsphere template to obtain hollow microspheres. It can also be eluted with a solvent first, and then calcined to remove the polymer microsphere template to obtain hollow microspheres.

Further, the volume ratio of the hollow part of the hollow microspheres can be controlled by controlling the particle size of the polymer microspheres and the thickness of the deposited metal layer or metal compound layer. Furthermore, when the metal layer and the metal compound layer are formed by the solution method, the concentration of the raw materials used to form the metal and metal compound in the solution can be adjusted, and then the thickness of the formed metal layer and metal compound layer can be controlled to realize the hollow part. Volume ratio adjustment.

Further, the shell layer can form holes by controlling the molecular growth and accumulation process of the shell layer.

The polymer microspheres can be polymer microspheres directly purchased from the market, such as polyethylene, polystyrene, polystyrene-divinylbenzene and other microspheres.

Further preferably, in the liquid embolic agent, by mass fraction, the polymer is 3%-10%, the developer is 20%-40%, and the solvent is 60%-75%.

In some of these embodiments, the polymer is any one of polyolefins, polyolefin alcohols, polymethacrylates, polyurethanes, polyesters, polyethers, polysiloxanes, and polyamides, or at least two of them of copolymers. Further, the above-mentioned copolymer can be polyacrylamide-polymethyl methacrylate, ethylene vinyl alcohol copolymer, polyethylene glycol-polyacrylate copolymer, etc., or it can be a water-insoluble natural polymer, such as fiber and its derivatives, etc. Further, copolymers include but not limited to random copolymers, block copolymers, alternating copolymers and graft copolymers.

Furthermore, the weight average molecular weight of the polymer is 10,000 to 400,000, preferably 100,000 to 200,000. Further, the above-mentioned polymer is a hydrophobic polymer or an amphiphilic polymer.

Further, the above-mentioned polymer is an amphiphilic polymer, and the molar content of the hydrophobic component of the polymer is greater than 50%, preferably greater than 60%. Among them, the hydrophilic component is the hydrophilic group contained in the side chain or main chain of the polymer, otherwise it is the hydrophobic component. The higher the content of the hydrophobic component, the shorter the precipitation time of the polymer in water, buffer or blood, and the lower the solidification rate. The solidification rate of the liquid embolism can be controlled by adjusting the ratio of the hydrophilic and hydrophobic components.

In some of these embodiments, the solvent is at least one of a biocompatible organic solvent, water and a buffer. Further, the biocompatible organic solvent includes at least one of dimethyl sulfoxide, N-methylpyrrolidone (NMP), ethanol and isopropanol, and these solvents have the advantage of low toxicity.

It can be understood that the solvent can be selected according to the type of the polymer, as long as it can make the polymer and the solvent form a uniform system. A homogeneous system here refers to a homogeneous clear solution or a homogeneous suspension. Further, the solvent can be a good solvent for the above polymer, that is, the solvent and the polymer can form a uniform clear solution, or the solvent and the polymer can form a homogeneous system under certain conditions.

Further, the above-mentioned polymer is a hydrophobic polymer or an amphiphilic polymer, and the solvent is a biocompatible organic solvent.

Another embodiment of the present invention also provides a preparation method of the above-mentioned liquid embolic agent, which only needs to mix the above-mentioned polymer, solvent and other components uniformly.

Further, common stirring, ultrasonic and other methods can be used for mixing, as long as the liquid embolic agent can form a homogeneous system.

Further, the polymer and the solvent may be firstly mixed by means of mechanical stirring to form a homogeneous polymer solution, and then the developer is added, and again mixed by means of mechanical stirring to form a uniform dispersion system.

Furthermore, in the step of forming a homogeneous polymer solution, methods such as temperature rise, temperature drop, and physical dispersion can be used to assist in promoting its dissolution.

After the liquid embolic agent forms a uniform dispersion system, it can be transported or pushed. After reaching the water or blood, with the diffusion of the solvent, the polymer in the liquid embolic agent precipitates out to form a soft embolism, and the embolism The developer in it ensures its good developing performance. In the embodiment of the present application, the hollow developer settles more slowly, which is beneficial to improve the uniformity of the developer in the embolic agent, so as to provide a good developing effect.

Another embodiment of the present invention also provides the application of the above-mentioned liquid embolic agent in the preparation of medical interventional devices or interventional therapy drugs.

Another embodiment of the present invention also provides a medical interventional device, a device body and a reagent disposed in the device body, where the reagent includes any one of the above-mentioned liquid embolic agents.

In some of these embodiments, the device body is a catheter. Furthermore, the inner diameter of the catheter is very small, which is called a micro catheter. Generally, the inner diameter of the microcatheter is 0.007-0.013 inch (inch).

Another embodiment of the present invention also provides a drug for interventional therapy, the drug for interventional therapy includes any one of the above-mentioned liquid embolic agents.

Furthermore, in addition to any of the above-mentioned liquid embolic agents, the drug for interventional therapy may also contain a drug or an active component of the drug as a therapeutic agent.

Furthermore, in addition to any of the above-mentioned liquid embolic agents, the interventional medicine may also contain other additives.

The above-mentioned liquid embolic agent can be used in interventional therapy, for example, in interventional hemostasis, vascular malformation and malignant tumor, including but not limited to interventional embolization of cerebral arteriovenous malformation (AVM), hematoma, and cerebral arteriovenous fistula (DVF), Treatment of peripheral varicose vessels and blockage of blood flow in tumors and other places.

The above-mentioned liquid embolic agent reaches the lesion area through the push of the microcatheter, touches the blood flow, and begins to solidify as the solvent diffuses. In the blood flow, the polymer in the liquid embolic agent slowly precipitates and solidifies to form an embolism, thereby achieving the purpose of blocking the vascular access and blocking the blood flow.

In some embodiments, the liquid embolic agent containing the developer of the hollow microsphere structure has a lower average bulk density and a lower viscosity, and the suspended metal microspheres have a certain "lubricity" in the polymer solution, which is beneficial to The pushing of the liquid embolic agent, and after the liquid embolic agent is pushed from the microcatheter, the microcatheter can be easily withdrawn, which reduces the risk of the microcatheter being pulled and causing blood vessels.

The technical features of the above-mentioned embodiments can be combined arbitrarily. To make the description concise, all possible combinations of the technical features in the above-mentioned embodiments are not described. However, as long as there is no contradiction in the combination of these technical features, should be considered as within the scope of this specification.

The above-mentioned embodiments only express several implementation modes of the present invention, and the descriptions thereof are relatively specific and detailed, but should not be construed as limiting the patent scope of the invention. It should be noted that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent for the present invention should be determined by the appended claims, and the description can be used to interpret the contents of the claims.

Claims (12)

1. A liquid embolic agent comprising: the developer is at least one of hollow microspheres made of metal materials, hollow microspheres made of alloy materials and hollow microspheres made of metal compounds.

2. The liquid embolic agent of claim 1, wherein said hollow microspheres are surface porous;

and/or the particle size of the hollow microsphere is 0.1-200 μm;

and/or the wall thickness of the hollow microsphere is 20 nm-20 mu m;

and/or the hollow part of the hollow microsphere accounts for 30-80% of the volume.

3. The liquid embolic agent of claim 1, wherein said metal is one of gold, silver, platinum, iridium, chromium, tantalum, bismuth, cobalt, tungsten, and barium;

the alloy is at least two of gold, silver, platinum, iridium, chromium, tantalum, bismuth, cobalt, tungsten and barium;

the metal compound is at least one of metal salt, metal oxide, metal carbide and metal nitride which are formed by at least one of gold, silver, platinum, iridium, chromium, tantalum, bismuth, cobalt, tungsten and barium and are insoluble in the solvent.

4. The liquid embolic agent of claim 1, wherein said polymer is 2% to 20% by mass, said developer is 10% to 40%, and said solvent is 40% to 88%.

5. The liquid embolic agent of any of claims 1 to 4, wherein said polymer has a weight average molecular weight of 1 to 40 tens of thousands.

6. The liquid embolic agent of any of claims 1 to 4, wherein said polymer is at least one of a hydrophobic polymer and an amphiphilic polymer;

and/or the solvent is at least one of a biocompatible organic solvent, water and a buffer solution.

7. The liquid embolic agent of any of claims 1 to 4, wherein said polymer is any one of polyolefin, polyolefin alcohol, polymethacrylate, polyurethane, polyester, polyether, polysiloxane, and polyamide, or a copolymer of at least two thereof;

and/or the solvent is at least one of dimethyl sulfoxide, N-methyl pyrrolidone, ethanol, isopropanol, water and buffer solution.

8. A method for preparing a liquid embolic agent, comprising the steps of:

the components of the liquid embolic agent of any of claims 1 to 7 are mixed homogeneously.

9. The method of producing according to claim 8, further comprising the step of producing the developer:

and forming a metal layer, an alloy layer or a metal compound layer on the surface of the polymer microsphere by taking the polymer microsphere as a template, and removing the core polymer microsphere template to obtain the hollow microsphere made of metal materials, alloy materials or metal compound materials.

10. Use of a liquid embolic agent according to any of claims 1 to 7 in the preparation of a medical interventional instrument or an interventional therapy.

11. A medical intervention device comprising a device body and a liquid embolic agent according to any of claims 1 to 7 disposed within the device body.

12. An interventional drug, characterized in that it comprises a liquid embolic agent according to any one of claims 1 to 7.

Images